A publication titled "Design and baseline characteristics of the CagriSema cardiovascular outcomes trial (REDEFINE 3)" appeared in American Heart Journal on October 6, 2026. CagriSema is a combination involving cagrilintide, which remains an unapproved research compound. The publication describes the trial design and baseline characteristics of participants in REDEFINE 3, a cardiovascular outcomes trial. No results or outcome data are included in this publication record. The article is indexed under PubMed ID 42838477. This type of publication typically establishes the structure, methodology, and starting population characteristics for a clinical trial before results become available. Readers should note that design and baseline publications do not report efficacy or safety findings. Further updates on this trial, including any results, would be expected in subsequent publications as the study progresses. For additional background on cagrilintide, including its research status and general characteristics, readers can consult the compound overview.
Publication Details CagriSema Outcomes Trial Design (REDEFINE 3)
See the full cagrilintide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42838477/